25th Annual Biotech in Europe Forum

FOR GLOBAL PARTNERING & INVESTMENT

8th - 9th of October 2025|MÖVENPICK HOTEL | BASEL | SWITZERLAND

20-MINUTE PRESENTERS:

BiotechnologyBio-Therapies

ARTCLINE GmbH

Rostock, Germany

Wed 8 Oct · 15:05 – 10:30

Sepsis remains one of the most urgent and costly medical challenges worldwide, with a critical need for innovative therapies. ARTCLINE is pioneering a novel allogeneic immune cell-based extracorporeal therapy for the treatment of septic shock, ARTICE®, designed to restore immune function and significantly improve patient outcomes. ARTICE® is the only therapy that targets both the early hyperinflammatory phase and the late immunoparalysis phase, addressing the root cause of sepsis immune dysfunction. By combining advanced immune cell modulation with an innovative plasma perfusion system, ARTICE® not only reduces inflammation and mortality but improves immune function and expedites long-term patient recovery. Unlike current treatments that focus on infection or inflammation alone, ARTICE® offers a comprehensive, personalized approach, resulting in superior clinical outcome. ARTCLINE has developed its patented ARTICE® Therapy to market readiness and regulatory approvals have been obtained already. A final clinical validation is currently being conducted in a multicenter study in Germany to evaluate the effectiveness of ARTICE®. A broad market launch is expected to take place in the second half of 2026, opening a new therapeutic window in sepsis treatment – in an area where options have been limited so far.

Biotechnology

BirchBioMed Inc.

King City, Canada

Wed 8 Oct · 14:05 – 10:30

BirchBioMed is revolutionizing the treatment landscape for fibrosis and certain autoimmune disorders through its advanced scientific innovations. Centered around the potent antifibrogenic properties of Kynurenic Acid (KynA), our treatments span from topical applications to systemic therapies, addressing critical healthcare challenges. KynA not only enhances extracellular matrix remodeling but also effectively reduces uncontrolled fibroblast proliferation and tissue cellularity, crucial for managing excessive scarring and organ fibrosis. In addition, our unique combination of KynA with antigen-presenting cells (APCs) offers a novel, promising and synergistic approach to the treatment of specific autoimmune disorders. Our therapies are not just treatments but potential cures, aiming to transform patient outcomes in diseases ranging from idiopathic pulmonary fibrosis to T1D and beyond. Through rigorous clinical trials and strategic global outreach, BirchBioMed is poised to deliver transformative solutions that promise a new era of healthcare.

Biotechnology

Cue Biopharma, Inc.

Boston, United States

Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation.

Biotechnology

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Shanghai, China

Wed 8 Oct · 14:45 – 10:30

ImmuneOnco is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies and one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems.

BiotechnologyInvestor - VCPharmaceuticals/LicensingTech Transfer

KHAN Technology Transfer Fund

Dortmund, Germany

Wed 8 Oct · 13:25 – 10:30

KHAN is an early-stage life sciences venture fund series with a mission to create value through collaborative drug discovery partnerships with leading academic innovators across Europe. The fund focuses on first-in-class therapies targeting areas of high unmet medical need and significant market potential. KHAN benefits from privileged access to cutting-edge scientific research from the Max Planck Society and other top-tier European academic institutions. The fund is managed by Khanu, a world-class team with deep expertise in drug discovery and venture investing. Through its strong partnership with the state-of-the-art Lead Discovery Center in Dortmund, Germany, KHAN achieves a remarkably low attrition rate and delivers highly efficient early-stage investments.

Oryzon Genomics, S.A.

Spain

Wed 8 Oct · 13:45 – 10:30

A public clinical-stage biopharma company developing epigenetics for CNS disorders and oncology/hematology. c.50 highly-qualified professionals located in Barcelona, Boston and San Diego. Listed in Spain, aiming at NASDAQ-listing. Two uncorrelated clinical-stage compounds: vafidemstat (Phase III-ready, CNS) and iadademstat (Phase II, oncology/hematology). Pioneering development of epigenetic drugs in CNS with vafidemstat, a safe LSD1 inhibitor, administered to + 425 subjects. The drug has shown promising results in reducing agitation/aggression in psychiatric patients in a Phase IIa basket trial, and in a global randomized, double blind Phase IIb trial in BPD (PORTICO, final results presented at ECNP-2024). Phase III in agitation/aggression in borderline personality disorder (BPD) in preparation. Vafidemstat is also being investigated for treating negative symptoms of schizophrenia in a randomized, double-blind Phase IIb trial (ongoing trial expansion to additional EU countries). Preparing a new Phase II trial in aggression in patients with ASD, including genetically-defined ASD subpopulations such as Phelan McDermid Syndrome. Iadademstat, a best-in-class LSD1 inhibitor, is in clinical development for AML, solid tumors and hematological disorders. PoC with strong clinical activity in combo with azacitidine in a Phase II in unfit AML patients, and encouraging signals in 2L-ED-SCLC. Highly encouraging data presented at ASH-2025 from ongoing trials in 1L AML (in combo with venetoclax/azacitidine, 100% ORR, 90% CR) and in R/RFlt3mut+ AML (in combo with gilteritinib, 67% CCR at the dose under expansion). Additional trials ongoing in MDS (in combo with azacitidine),1L SCLC (in combo with ICI), and in MPN (in combo with ASTX727). Expanding into hematological indications: sickle cell disease (PhIb trial approved by EMA, recruiting), essential thrombocythemia (PhII in prep).

BiotechnologyPharmaceuticals/Licensing

Sen-Jam Pharmaceutical

Huntington, United States

Wed 8 Oct · 13:45 – 10:30

Sen-Jam Pharmaceutical: Revolutionizing Inflammatory and Metabolic Care Sen-Jam Pharmaceutical is pioneering a revolutionary approach to inflammatory and metabolic disorders with our proprietary PAIR (Pleiotropic Anti-Inflammatory Regulators) technology. By working with the body’s innate wisdom, our precision anti-inflammatories modulate inflammation at its source, addressing systemic risks linked to chronic conditions like obesity, metabolic dysfunction, and autoimmune diseases—all without suppressing the immune system. We are leading the next evolution in healthcare, delivering innovative treatments that enhance vitality, extend health spans, and redefine how the world heals. What Problem Are We Solving? Chronic inflammation is a silent driver of countless diseases, from metabolic disorders like obesity and MASLD to autoimmune and everyday health challenges. Yet, current treatments often suppress the immune system, creating new risks. The world needs a smarter, safer way to address inflammation and metabolic dysfunction at their core without compromising overall health. Sen-Jam Pharmaceutical’s breakthrough PAIR technology is designed to solve this urgent problem, offering precision anti-inflammatory and metabolic solutions that preserve vitality, support weight management, enhance productivity, and improve lives. What’s Our Unfair Advantage? Sen-Jam Pharmaceutical’s “unfair advantage” lies in the exceptional caliber of our team and the groundbreaking potential of our proprietary PAIR technology. Our scientific advisors, with decades of experience at world-renowned institutions like the Mayo Clinic, Boston Medical Center, Harvard School of Public Health are Ivy League-published experts solving the world’s toughest health challenges. This unparalleled expertise, combined with our precision-driven approach to inflammatory and metabolic care, positions Sen-Jam to disrupt the market and emerge as a transformative unicorn in healthcare.

STALICLA SA

Switzerland

Wed 8 Oct · 14:05 – 10:30

STALICLA SA is a Swiss clinical-stage biopharmaceutical company, revolutionizing the treatment of neurodevelopmental (NDD) and wider neuropsychiatric disorders. The company has developed a clinically validated neuro precision development platform, successfully delivering stratified patient subgroups and advancing tailored treatment options. Its lead NDD asset, STP1, and a second NDD asset are set to enter Phase 2 trials with expected readouts within 30 months. STP7 (Mavoglurant), is also being advanced for Phase 3 trials, fully funded by the US government with discussions underway for out-licensing. We are currently raising a series C of $60m to recite the Phase 2 precision autism program development.

Biotechnology

Stromal Therapeutics AG

Basel, Switzerland

Thu 9 Oct · 12:00 – 10:30

Stromal Therapeutics AG is a pioneering Swiss biotech company dedicated to developing cutting-edge immunotherapies targeting tissue cytokines and their inhibitors, predominantly produced by stromal cells. The company has successfully raised over 1 million Swiss francs in seed funding and achieved several critical milestones: • The lead antibody, STx_001 has been humanized and shows therapeutic effects in acute myocarditis and prevention of cardiac fibrosis. • A direct path from Phase II trial to market is clearly outlined through orphan drug designation for the first indication • The company is seeking Series-A financing to advance IND production, first-in-human testing, and preparation of proof-of-concept trials The company is currently seeking Series A financing to advance clinical development and envisions to accelerate market entry through orphan drug designation.

Biotechnology

Teitur Trophics ApS

Aarhus, Denmark

Wed 8 Oct · 14:25 – 10:30

Teitur Trophics: Advancing Neurodegeneration Treatments Teitur Trophics is a biopharmaceutical company dedicated to developing transformative treatments for neurodegenerative diseases, including Huntington's Disease, Parkinson's Disease, and Frontotemporal Dementia. The company company is founded on pioneering research conducted at Aarhus University, where scientists uncovered a novel pathway that plays a critical role in maintaining neuronal survival and function. This pathway uniquely targets three key pillars of neurodegeneration: improving mitochondrial function, enhancing lysosomal function, and preserving synaptic integrity. By addressing these interconnected mechanisms, we aim to protect and restore the health of neurons, ultimately slowing or even halting disease progression. Our lead program, TT-P34, represents a groundbreaking advance in the field of neurodegeneration. TT-P34 is a first-in-class peptide therapy that has demonstrated potent efficacy in preclinical studies, including its ability to slow or halt disease progression in animal models of Huntington's Disease and Parkinson's Disease. Importantly, the compound is designed with patient convenience in mind, offering a once-weekly subcutaneous injection, reducing treatment burden and improving adherence. With a strong foundation of preclinical data supporting its safety and efficacy, TT-P34 is set to enter first-in-human studies in Q2 2025, where it will initially be tested in healthy volunteers. This milestone marks a significant step toward bringing a much-needed, disease-modifying therapy to patients suffering from devastating neurodegenerative disorders. At Teitur Trophics, we believe that innovation in science is the key to addressing the complex challenges of neurodegeneration. By focusing on a holistic approach to neuronal health and leveraging cutting-edge research, we are committed to developing therapies that not only extend life but also preserve its quality for patients and their families.

Tessara Therapeutics Pty Ltd.

Australia

Thu 9 Oct · 12:20 – 10:30

We bridge the gap between preclinical and clinical neuroscience by evaluating the performance of neurology therapeutic assets on the most clinically relevant in vitro platform available. Tessara leads the world with our RealBrain drug screening platform, combining reproducibility and scalability with human physiological relevance in 3D in vitro models. RealBrain models feature functional neural networks and closely mimic human neurophysiology. The RealBrain microtissues are cultured from neural precursor cells mixed with biomaterials in a one-step casting process that mitigates the typical limitations of in vitro technologies. Automation, developed through partnerships with robotics leaders, enables consistent, rapid production of microtissues with minimal variation. Furthermore, AI algorithms transform the neural architecture into digital 3D maps for automatic detection and quantification of neural network architecture. This allows precise assessment of drug effects on various cell populations and neural connectivity. Unique in its capability for high-throughput, high-content analysis, the RealBrain platform combines sophisticated biology with user-friendly handling, to accelerate drug discovery and predict which drug candidates are more likely to be efficacious in human clinical trials.

10-MINUTE PRESENTERS:

Biotechnology

Alder Therapeutics AB

Solna, Sweden

Wed 8 Oct · 16:00 – 10:30

We are one of the leaders in Replacement Cell Therapy and aim to treat Retinitis Pigmentosa, an inherited blindness with almost no treatment options today. We have shown our pre-clinical and CMC to both FDA and EMA and received positive feedback to continue our development. Our manufacturing is similar to biologics both in manufacturing and price, we can produce a dose for less than 10 000 €. We are raising 22 M€ to generate clinical proof of concept in a small Phase I/IIa trial where we expect to get secondary efficacy data. From there it is expected that we only need 50-100 more patients in a Phase III study to apply for market approval. We are building a syndicate now and are looking for the final partner. Will you join us and give hope to the Retinitis Pigmentosa patients?

Biotechnology

AM-Pharma B.V.

Utrecht, Netherlands

Wed 8 Oct · 15:40 – 10:30

AM-Pharma, a private clinical stage biotech company based in Utrecht, the Netherlands, is developing its proprietary recombinant human alkaline phosphatase therapeutic, ilofotase alfa as an enzyme replacement therapy administered sc for the rare disease hypophosphatasia, clinical PoC achieved, the compound can be on the market by 2030 and the market potential exceeds EURO 1B.

Biotechnology

Amporin Pharmaceuticals AG

Basel, Switzerland

Wed 8 Oct · 14:45 – 10:30

Amporin is developing the first class of oral drugs that could stop and reverse over 50 deadly degenerative diseases, uniquely by repairing the holes in cell membranes formed by toxic misfolded protein oligomers, allowing diseased cells to fully recover and restore homeostasis. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson's disease.

Pharmaceuticals/Licensing

Arphamid Therapeutics SAS

Saint Louis, France

Thu 9 Oct · 11:50 – 10:30

Arphamid Therapeutics SAS seeks investors to finance the IND-enabling development first-in-human proof-of-mechanism testing, and first demonstration of clinical efficacy of RF4662, our first-in-class, orally-active small molecule GPR103 receptor antagonist. RF4662 holds promise in the management of obesity, depression, and opioid dependence. Our first target indication is to reduce the frequency of breakthrough pain episodes in patients receiving medically-required chronic opioid therapy.

BioinformaticsBiotechnology

biotx.ai GmbH

Potsdam, Germany

Causal mapping of the genome: Unveiling the genes that cause or influence biological effects, traits, or diseases.

Biotechnology

Cereno Scientific AB

Mölndal, Sweden

Wed 8 Oct · 15:15 – 10:30

Cereno Scientific is pioneering treatments to enhance and extend life. The company’s innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling and improvement of right heart function as observed in a Phase IIa trial in patients with PAH. CS014, a new chemical entity with disease-modifying potential, showed favorable safety and tolerability profile in a Phase I trial. CS014 is HDACi with a multimodal mechanism of action as an epigenetic modulator having the potential to address underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as IPF and PH-ILD. Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent, and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se.

Biotechnology

CIS BIOPHARMA AG

Bubendorf, Basel, Switzerland

Wed 8 Oct · 11:10 – 10:30

CIS BIOPHARMA – Pioneering Targeted Cancer Therapies CIS BIOPHARMA helps cancer patients live longer, better lives. Located in the Basel area, Switzerland, we are a biotech company with over 50 years of activity in Life Sciences. We develop the next generation of targeted cancer therapies with a focus on Antibody Drug Conjugates, ADCs, and radiopharmaceuticals. We target cancers with high unmet medical need by addressing both established and emerging oncology targets. Through our proprietary platforms, we create first-in-class and best-in-class immunoconjugates designed to improve patient outcomes. Our technologies inlcude advanced protein engineering, linker and payload design, and bioconjugation, enabling innovative approaches to precision oncology.

Biotechnology

Curlim

Limoges, France

Thu 9 Oct · 11:10 – 10:30

Curlim is a late stage preclinical biotech company developing an innovative encapsulation platform designed to improve the therapeutic efficacy of bioactive molecules. First applications target hereditary peripheral neuropathies and neurodegenerative diseases.

Lead indication is CMT1a, the most common hereditary neuropathy, causing lifelong progressive motor disorders beginning in childhood.

At present, there is no pharmacological treatment for nervous disorders known as peripheral neuropathies. Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy (HPN). Therapeutic strategies remain very limited and do not address the cause of the disease, but mainly its symptoms. This lack of pharmacological treatment is particularly dramatic in the case of hereditary peripheral neuropathies, as they are diffuse and often manifest very early in the patient's life and persist throughout their lifetime.

Our solution has been developed by LImoges labs (neuro and sciences) and consists of a Platform technology. The platform is a novel cationic beta-cyclodextrin crystalline-nanocrystal (B-CD/CNC) nanocarrier system for improved solubility, bioavailability, and cellular penetration of APIs.

Our compund CLM001 Targets Oxidative Stress, Heavily Implicated in Peripheral Neuropathies.

CLM001 obtained unprecedented and spectacular therapeutic effects demonstrated on 2 CMT1A animal models showing anti-inflammatory, antioxidant, and remyelinating effects, with no toxicity signals.

CLM001 shows a significant rescue in the nerve function. When treated for a total of 12 weeks, CLM001 significantly improved balance/speed and increased the nerve conductivity.

In parallel, Primary and secondary modes of action have been characterized.

From a regulatory point of view, Orphan Drug Designation has been granted both by EMA and by FDA.

CMC is finalized and next development stage will be the launch of pre-clinical toxicology study.

Biotechnology

Cytora

Yokneam, Israel

Thu 9 Oct · 12:40 – 10:30

A stem cell biopharmaceutical company. Cytora developed a revolutionary technology to produce off the shelf therapeutic of human Oral Mucosa Stem Cells to treat challenging diseases, including chronic wounds such as diabetic foot ulcers (DFUs) and neuro degenerative diseases such as Parkinson's Disease, Multiple System Atrophy (MSA)and others. The Company successfully completed a Phase 1/2a study for treating DFUs and is currently conducting a Phase 1 study for the treatment of MSA. Following a successful Pre-IND meeting with the FDA, the company is going to start a phase 2b clinical trial in US in DFU, under FDA, with ~100 patients in 15 sites. A phase 2 is planned in MSA under IND FDA. The company is currently raising $30M to fund the Phase 2b study In DFU and MSA in US under FDA IND. In addition, the company is looking for a CDMO partnership in USA, to support U.S.-based access to patients under Florida’s new stem cell legislation from July 1st, 2025 (SB 1768).

Biotechnology

Galimedix Therapeutics, Inc.

Kensington, United States

Thu 9 Oct · 11:40 – 10:30 · Track E

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies for serious brain and retinal diseases.

Lead program, GAL-101 (eye drops), is in a Phase 2 trial for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration (dAMD). An oral formulation of GAL-101 has successfully completed Phase 1 testing and shown to be safe, well tolerated, and effectively crosses the blood-brain barrier. Target engagement could be shown. Phase 2 trials in Alzheimer’s (oral) and glaucoma (eye drops) are planned. A next-generation compound, GAL-301, is in pre-clinical testing.
Galimedix is looking for crossover financing to progress GAL-101 to clinical proof of concept in Alzheimer´s disease and to advance its earlier-stage programs ahead of a planned US IPO.

Galimedix has signed a licensing and equity deal with Théa Open Innovation for co-development and commercial rights to GAL-101 in ophthalmology, excluding APAC and is pursuing additional regional partnerships.

Recent highlights include the successful completion of the first-in-human study of the oral version of GAL-101, data presented at CTAD, and the ongoing Phase 2 eDREAM trial in GA, with LPI anticipated this year.

Biotechnology

Hoba Therapeutics ApS

Copenhagen N, Denmark

Wed 8 Oct · 15:50 – 10:30

Hoba Therapeutic is an early-stage biotech based in Denmark developing innovative treatments for chronic pain disorders and hearing loss. Both indications have a clear unmet medical need for safe and efficacious treatments for millions of patients. The lead compound HB-086 is a novel biopharmaceutical drugs for the treatment of chronic neuropathic pain. HB-086 is a non-opioid with long-lasting effect and an attractive safety profile (non-addictive). Unlike most therapeutic approaches that merely address pain symptoms (e.g., opiates, sodium channel blockers), HB-086 targets the peripheral nerve pathology, the underlying cause of neuropathic pain. Hoba is currently finalizing the clinical trial application enabling activities and plan to submit a CTA in EU in Q1 2026, and initiate first-in-human studies in Q2 2026 Hoba announced on 11 Dec 2023 the completion of Series A first close of EUR 23 M/USD25 M securing funding for the preclinical lead compound, HB-086 (non-opioid) to initiate phase 1A/1B trial in chronic neuropathic pain. Hoba Therapeutics is backed by an international investors; e.g. Novo Holdings, Eir Ventures, EIFO, Indaco Venture Partners, Medical Incubator Japan, European Innovation Council Fund. The second close will fund activities enabling phase II readiness for additional indications within neuropathic pain (e.g. diabetic peripheral neuropathy, Lower back pain, etc.). Hoba Therapeutics is led by an experienced management team with a successful track record and completion of several exits (IPO's and acquisitions). We are interested in meeting with investors, pharma and biotech, and will decline invitations from CRO/CDMO's.

Biotechnology

Ipsomel Innovations

Aubagne, France

Wed 8 Oct · 11:20 – 10:30

Ipsomel offers a disruptive solution for the purification of proteins, a critical step also difficult to get under control, that generates 60% of the total cost of production of bio-medecines. Including as well Equipment as associated processes this technology is positioned against Chromatography columns suppliers such as Sartorius, ThermoFischer, Merck-Millipore or 3M. Ipsomel actually replaces Chromatography by Electrophoresis, which based on isoelectric point allows a much better selectivity of the targeted protein in separating enantiomers and stereoisomers. WHat Chromatography doesn't always succeeds to reach even after multiple purification cycles. Furthermore, as such the cost of the purification can be reduced by 40% while reducing dramatically the environmental impact of such production. Working in continuous flow, as opposed to Chromatography, Ispomel Equipments can work under automation, requiring less labor, much smaller utilities, avoid procuring and regenerating expensive chromatography gels, which require also large volumes of solvants. This results in a dramatic cost reduction and much less waste.

Biotechnology

JLP Health GmbH

Vienna, Austria

Wed 8 Oct · 14:55 – 10:30

JLP Health is a young Austrian biotech company that leveraged its unique genetic screening platform to uncover a novel treatment combination for the deadliest brain tumor - glioblastoma. Seamlessly integrating into standard of care therapy, this approach offers new hope to a broad patient population, where it is most needed. JLP Health currently prepares a Phase 1 clinical trial and seeks new investors and partners to drive clinical development.

Biotechnology

Ksilink

Strasbourg, France

Thu 9 Oct · 11:30 – 10:30

Ksilink is a French TechBio company transforming drug discovery through a proprietary platform that integrates patient-derived cellular models with advanced AI-powered, high-throughput phenotypic screening. Headquartered in Strasbourg, the company offers unique capabilities to accelerate the discovery of first-in-class therapeutics with unmatched clinical success rate.

BiotechnologyPharmaceuticals/Licensing

LIfT BioSciences Ltd.

London, United Kingdom

Wed 8 Oct · 11:30 – 10:30

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess. The company is working with a range of pharmaceutical license partners to develop a portfolio of CAR-IMAN cell therapies to deliver complete remission across all solid tumours before the decade is out. LIfT BioSciences was founded by Alex Blyth following the death of his mother to pancreatic cancer. Technology Immuno-Modulatory Alpha Neutrophil progenitors (IMANs) produced from iPSCs or HSCs using our N-LIfT Platform Stage Pre-clinical work completing, IND filing Focus Solid Tumours with high unmet medical need, starting with SCC-NSCLC, PDAC, HNSCC, UCC Patents 2016 Filing Granted, 6 Patents with FTO Current Raise £25m+ Series A. Pharma license discussions underway. Recent Achievements - Successful production from iPSCs and GMP ready production from HSCs at 10L - Increase T-cell and NK cancer killing 250% in Lab-on-chip tumour model - Unmodified IMANs shows comprehensive solid tumour organoid killing (superior to Keytruda & Abraxane) in NSCLC, PDAC - HER-2 CAR IMANs increase cancer cell killing x5 over the already potent unmodified LIfT IMANs have preclinical validation of all of the characteristics required to overcome the challenges to achieving sustained remission in solid tumours.

Biotechnology

Nanolattix

Taiyuan, China

Wed 8 Oct · 16:10 – 10:30

Nanolattix is seeking collaborative licensing and development partnerships for global expansion. Nanolattix focuses on ADC/RDC (RLT) oncology therapeutics. T320-ADC has received IND approval in the US, Australia, and China. Received Orphan Drug Designation for Pancreatic Cancer in the US. Phase 1 clinical trials began in March 2025. ADCs (2), bispecific ADCs (8), and RDC (8), including dual payload, drug candidates with promising preclinical data. Various indications in solid tumor, including Lung, Pancreatic, Colorectal, Gastric, etc.

BioinformaticsBiotechnologyDigital HealthMedical DevicesTherapeutic research

Neurochlore

Marseille, France

Wed 8 Oct · 12:10 – 10:30

Neurochlore is a pioneering French start-up dedicated to studying the brain’s fundamental mechanisms in perinatal period. Built on the innovative concepts of Neuroarchaeology and GABAergic polarity, the company has shed light on the crucial role of the excitation/inhibition balance in building a functional brain. This imbalance is now recognized as a central factor in numerous neurodevelopmental disorders—most notably autism—as well as in certain brain pathologies such as tumors. Building on this strong scientific foundation, Neurochlore structures its research and innovation around two strategic axes : Axis 1 – Biomedical Research & AI: Focused on artificial intelligence and computational analysis applied to medicine and biology. This axis focuses on developing tailored data analysis solutions for both structured datasets and complex imaging data (MRI, microscopy, CT scans, etc.), enabling the detection, prediction, and modeling of biological processes. It also advances in-house projects to create new diagnostic support tools, accelerating the path from data to discovery. Axis 2 – Oncological Therapeutics: Dedicated to the development of innovative approaches for complex and treatment-resistant brain tumors. By combining two anticancer molecules and integrating research on the neuronal environment and hyperexcitability that drive tumor progression, this axis explores a paradigm shift in brain cancer therapy, with promising extensions to other pathologies involving disrupted chloride homeostasis. By bringing together fundamental science, technological innovation, and translational medicine, Neurochlore is shaping the future of neuroscience and tomorrow’s therapies. Neurochlore is active participants in the IBEN Project (Institut Ben-Ari d’Innovation), a future high-tech biotech hub in Marseille. Located on the Luminy science campus, the 6,600 m² building—designed by Rudy Ricciotti in partnership with Eiffage Immobilier and Tivoli Capital—is set to open by 2027, hosting laboratories, offices, and collaborative spaces dedicated to cutting-edge biotech and health AI companies.

BiotechnologyPharmaceuticals/Licensing

NoToVir Srl

Novara, Italy

Thu 9 Oct · 11:00 – 10:30

NoToVir is an Italian biotech company developing Selisistat, a first-in-class, clinically de-risked SIRT1 inhibitor with dual activity as a radiosensitizer and chemosensitizer for HPV-driven cancers. Selisistat is a targeted therapy that restores p53 tumor suppressor activity by inhibiting SIRT1, a mechanism shared across HPV-related malignancies including oropharyngeal, cervical, anal, vulvar, and penile cancers. The company holds exclusive worldwide rights to a patent covering the use of Selisistat across all HPV-driven cancers. Leveraging an already established regulatory dossier, NoToVir is ready to initiate a randomized, double-blind, placebo-controlled Phase IIb trial in patients with HPV-positive oropharyngeal cancer receiving radiotherapy who are unfit for cisplatin. This fragile and underserved population represents an ideal setting for demonstrating clinical proof of concept. Importantly, NoToVir has generated strong preclinical data showing that Selisistat enhances the efficacy of both radiotherapy and cisplatin. A successful outcome in the head and neck setting would provide a strong rationale for rapid expansion into additional HPV-related indications, where the same SIRT1-p53 dependency is observed. This shared biology, combined with broad IP coverage, enables a built-in pipeline strategy across multiple cancer types. HPV-driven cancers account for approximately 5% of all malignancies worldwide, yet the therapeutic market remains wide open, with no approved targeted therapies and substantial unmet need across multiple tumor types. With a clear mechanism of action, solid IP protection, and a Phase IIb trial ready to initiate, NoToVir is addressing a critical unmet need in precision oncology. Selisistat offers a fast-to-clinic, low-risk development path, supported by an established regulatory dossier and focused initial indication. The company is supported by a multidisciplinary team that includes clinicians, such as medical oncologists and radiation oncologists, regulatory experts, the scientific inventor of the Selisistat patent, and biotech business professionals. NoToVir is currently seeking investors and strategic partners to support its clinical and commercial roadmap.

Biotechnology

Oncovita

Paris, France

Wed 8 Oct · 11:50 – 10:30

Oncovita is a pre-IND/CTA biotech company based in Paris and a spin-off from the Institut Pasteur. We are developing Measovir®, a novel oncolytic virus platform based on genetically modified measles vaccine strains. This approach combines a strong safety profile with targeted immune-mediated tumor destruction. Our lead candidate, MVdeltaC, is expected to enter a First-in-Human Phase I clinical trial in 2026—both as monotherapy and in combination with an immune checkpoint inhibitor. This will be followed by a Phase IIa study targeting Pleural Mesothelioma (for which we recently received Orphan Drug Designation from the FDA) and Triple-Negative Breast Cancer. Robust preclinical data, a promising case report, and scientific backing from the Institut Pasteur provide strong confidence in the therapeutic potential and risk profile of our platform. We are currently raising funds to initiate our first clinical trial—an important milestone toward clinical validation and long-term value creation. We believe this is a compelling opportunity to contribute to a potentially transformative approach in solid tumor treatment.

Biotechnology

Pilatus Biosciences SA

Epalinges, Switzerland

Thu 9 Oct · 10:50 – 10:30

Pilatus Biosciences, a US/Swiss -based R&D startup originating from the Ludwig Institute for Cancer Research (Lausanne), stands on the cutting-edge of developing First-in-Class Biologics, focusing on metabolic checkpoints. Our pioneering approach, backed by the Cancer Research Institute (New York), targeting Immunometabolism triggers immune microenvironment reprogramming to combat cancer.

Senya Therapeutics

United Kingdom

Thu 9 Oct · 11:40 – 10:30 · Track A

Senya Therapeutics is pioneering an anti-leucine-rich α-2 glycoprotein 1 (LRG1) therapeutic platform to address major unmet clinical needs in nephrology, oncology, pulmonary disease and ophthalmology.

BiotechnologyDrug DeliveryPharmaceuticals/Licensing

UPyTher B.V.

Eindhoven, Netherlands

Wed 8 Oct · 12:00 – 10:30

UPyTher is a preclinical-stage drug development company pioneering first-in-class intraperitoneal therapies for the treatment of peritoneal carcinomatosis (PC) — a devastating complication of colorectal, ovarian, and gastric cancers. PC affects up to 40% of colorectal, 30% of gastric and 80% of ovarian cancer patients, causing more than 1.3 million cancer patients with PC annually worldwide. Current therapies fall short. Systemic treatments rarely achieve effective drug levels in the peritoneal cavity and often cause high systemic toxicity. Direct intraperitoneal delivery with existing drugs has also failed, as these medicines rapidly leak from the cavity before reaching therapeutic exposure. This delivery bottleneck leaves PC as a largely untreatable condition, despite the promise of chemotherapy, targeted drugs, and immunotherapies. UPyTher’s solution is a proprietary polymer-based formulation platform designed specifically for the peritoneal cavity. Our medicines are administered as a liquid that distributes evenly before forming a robust gel depot. This ensures sustained local drug release, reduced systemic toxicity, and compatibility with a broad range of therapeutic classes — from chemotherapies to checkpoint inhibitors. Our lead candidate, UPT-211, is a novel intraperitoneal formulation of mitomycin C for colorectal PC. In preclinical studies, UPT-211 achieved a 78% survival rate in a lethal model, with systemic exposure four times lower than intraperitoneal therapy using traditional mitomycin C. By leveraging a well-characterized chemotherapy, UPyTher pursues a de-risked, cost-efficient development path while establishing intraperitoneal therapy as a new standard and paving the way for its pipeline candidates. To date, UPyTher has raised €3.2 million in equity and non-dilutive funding. We are seeking €20 million to advance UPT-211 into GLP toxicology and Phase 1a/b trials (first data expected by end of 2027) and advance our pipeline programs on colorectal and ovarian PC. UPyTher is transforming peritoneal therapy, turning PC from a lethal complication into a treatable disease.

Vandria SA

Switzerland

Wed 8 Oct · 15:05 – 10:30

Vandria is a clinical-stage biotech company based in Lausanne, Switzerland, developing first-in-class therapies targeting mitochondrial dysfunction to treat age-related diseases. Our lead compound, VNA‑318, is a brain-penetrant mitophagy inducer currently in Phase 1 clinical trials for neurodegenerative conditions. Backed by over $30 million in Series A funding and supported by European innovation grants, Vandria aims to restore cellular resilience and improve health span through mitochondrial science.

RISING BIOTECH STARS SESSIONS:

Biotechnology

Adularia AG

Zürich, Switzerland

Thu 9 Oct · 15:00 – 10:30

Adularia is a pre-clinical stage biotech spin-off from the University of Zurich. We develop pioneering small molecule cancer immunotherapies, which are based on insights from the symbiotic interplay between gut microbes and the immune system. We have identified and characterized a novel therapeutic target for immuno-oncology through the discovery of a mechanism by which bacterial metabolites activate a potent anti-tumor immune reaction in tumor-residing macrophages. Leveraging this discovery, we are developing synthetic molecules that replicate and enhance this mechanism, creating a targeted and well-tolerated immunotherapy aimed at reactivating immune cells within the tumor microenvironment.

Biotechnology

Arivin Therapeutics Ltd.

Helsinki, Finland

Thu 9 Oct · 15:00 – 10:30

For the last few decades, resistance mechanisms in bacterial pathogens have evolved faster than our ability to develop new and effective antibiotics. Increasing antimicrobial resistance is growing into a healthcare crisis, with 4,7 million associated deaths in 2021, a number that is expected to rise to 10 million deaths per year by 2050, with an estimated $2 trillion in annual global economic losses. At Arivin Therapeutics, we focus on future-proof antimicrobial strategies: Therapies designed to effectively treat resistant bacterial pathogens, without promoting rapid resistance themselves. Our therapies target bacterial virulence factors by directly binding and neutralizing bacteria’s most deadly weapons, their toxins, and by interacting with its extracellular polymeric substance, which helps to directly breakdown bacterial biofilms. The therapies are not bacteriostatic or bactericidal and therefore evade rapid resistance development, providing a more sustainable treatment that addresses the ongoing threat of bacterial resistance. The combined effect significantly lowers the burden of pathogens and limits their ability to spread the infection. The therapy is effective against Top-priority Gram-negative pathogens Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae. Our lead program, Viri-01, is advancing towards clinical trials for Cystic Fibrosis (CF) and non-CF bronchiectasis (NCFB) patients with chronic lung infections. As an inhaled therapy for respiratory infections, Viri-01 is designed to deliver multiple patient benefits by binding and neutralizing bacterial toxins to reduce inflammation and protect lung tissue, while targeting virulence factors that drive chronic infection, thereby disrupting bacterial persistence and supporting faster recovery. Through the combined effects of lowering inflammation and bacterial burden, Viri-01 is expected to improve lung function over time, while also weakening bacterial resilience and working synergistically with antibiotics to reduce the need for prolonged antibiotic therapy.

Pharmaceuticals/Licensing

BIOCELL LTD.

Gerrards Cross , United Kingdom

Thu 9 Oct · 15:00 – 10:30

Focused on R&D of patented, preclinical chemopreventive drug candidates for hormone driven solid tumors – Breast, Ovarian and Prostate cancer. Increased cancer incidence and rapidly acquired resistance to current single target chemotherapy drugs, highlight the urgent need for long term chemoprevention as a viable alternative to chemotherapy. We have identified two drug candidates with demonstrated cancer inhibitory effect, without side effects and high chemoprevention potential in large demographics. OBX for BC & OvCa chemoprevention OPX for PC chemoprevention and sperm quality improvement Market for Primary Chemoprevention Over 43% of women 40-75 have heterogeneously/extremely dense breasts (NIH) with 4-6 fold higher BC risk, as well as increased OvCa risk Market for Secondary Chemoprevention Breast cancer recurrence occurring 10-32 years after BC primary diagnosis in close to 50% of cases. Poor current treatment adherence to current SOC therapy contributes to high rate of relapse.

AcademiaBiotechnologyCRO

Chromos Labs

Carlton, Australia

Thu 9 Oct · 15:00 – 10:30

Chromos Labs is a University of Melbourne spin out developing next generation quantum biosensing tools to transform neurological drug discovery. Neurological disorders affect nearly half the world’s population, yet the majority of neuropharmaceutical candidates fail in late-stage clinical trials due to the lack of predictive, human-relevant preclinical models. Existing tools such as multi-electrode arrays, patch clamping, or calcium dyes are either invasive, low throughput, or unable to capture functional network activity with sufficient resolution to enable functional phenotypic assays. Our flagship platform, Diamond Voltage Imaging Microscopy (DVIM), is a quantum-enabled, label-free voltage imaging system. It uses engineered diamond crystals embedded with atom-scale sensors that change their light emission in response to neuronal electrical activity. This enables real-time, high-resolution monitoring of live human neurons and brain organoids, without dyes or wires, effectively acting as a high-speed “camera” of neuronal function at sub-cellular resolution. DVIM unlocks the ability to perform automated disease phenotyping and functional drug response assays in vitro, bridging the gap between cell models and human outcomes. By providing more accurate early-stage readouts, our technology empowers pharmaceutical and biotech R&D teams to identify and de-risk promising compounds sooner, accelerating the path to effective therapies. The platform is currently at Technology Readiness Level 5, with successful demonstrations of extracellular recordings of mammalian action potentials.

Biotechnology

ClearideBio AG

Basel, Switzerland

Thu 9 Oct · 15:00 – 10:30

ClearideBio (ex-NBE team; $1.4B exit) develops safer, smarter ADCs. Three design pillars: PK/ADME-tuned safer payloads, bispecific/masked antibodies, and dual-payloads. Lead CRB-001 (bispecific safer Topo1-ADC; prostate & lung) enters IND-enabling; FIH ~15 months; 2nd-in-class with differentiated preclinical safety. Lean CH/US/CN footprint drives rapid PoC; partnership-ready in a ~$9.7B ADC market growing toward ~$20B by 2028.

Biotechnology

DCRM Sciences, Inc.

Newark, United States

Thu 9 Oct · 15:00 – 10:30

DCRM Sciences is developing an AEP inhibitor "11A" targeting Alzheimer's Disease. 11A reduces neuroinflammation, tau pathologies, and amyloid-beta-induced pathologies. Targeting all the hallmarks covering Alzheimer's. 11A is a potent, selective, and brain-penetrant compound. Furthermore, 11A restores and improves cognition, memory, and learning capabilities. In addition, 11A provides a strong neuroprotective profile, preserving neuronal density, reducing apoptosis in the brain, preserving synaptic protein expression, and inhibiting brain volume reduction. Finally, 11A has proven to be very safe, with no signs of toxicity at administered doses.

Diamante Società Benefit Srl

37135, Italy

Thu 9 Oct · 15:00 – 10:30

Diamante Società Benefit is an Italian biotechnology company pioneering innovative therapies for autoimmune diseases through its proprietary plant-based nanomaterial platform. The company’s lead program is advancing in preclinical development for Rheumatoid Arthritis (RA), one of the largest autoimmune markets with high unmet medical need. RA affects millions of patients worldwide, and despite multiple approved therapies, many patients fail to respond or experience adverse effects, leaving room for new approaches that address the underlying immune dysfunction. Diamante’s platform is designed to restore immune tolerance in a targeted and durable way, offering a differentiated mechanism of action with the potential to expand beyond RA into additional high-value autoimmune indications such as multiple sclerosis and lupus. Together, these markets represent a global opportunity exceeding €40 billion and are expected to continue growing over the next decade. The company’s business model is structured to maximize value creation while managing risk. Diamante plans a licensing exit after Phase 2a (expected in 2027), in line with investor preferences for post-proof-of-concept deals. Potential options include licensing agreements with major pharmaceutical companies, trade sales to biotech consolidators, or, at a later stage, an IPO if strategically aligned. At the same time, Diamante maintains the flexibility to continue raising capital to advance its programs further, thereby retaining more value for shareholders. As a Benefit Corporation, Diamante integrates social and environmental goals into its strategy, aligning with ESG principles increasingly prioritized by global investors. The company combines cutting-edge science, a scalable manufacturing platform, and a commitment to sustainability to create long-term value for patients, partners, and stakeholders.

Biotechnology

FINNCURE Ltd.

Espoo, Finland

Thu 9 Oct · 15:00 – 10:30

FINNCURE is a biotech company focusing on solutions for targeted therapies and targeted delivery of active pharmaceutical ingredients.

BiotechnologyTherapeutics

Loma Therapeutics

Copenhagen, Denmark

Thu 9 Oct · 15:00 – 10:30

Our mission is to revolutionize the cancer treatment field by developing a best-in-class therapeutic vaccine to treat Human Papillomavirus-positive (HPV+) cancers such as head-neck, cervical, anal, and penile cancers while avoiding cancer relapse and morbidities. Every year 800,000 people get diagnosed with HPV-positive cancer which accounts for 5% of all global cancers. The standard of care treats cancer but not the root cause: the underlying HPV infection. 25% of patients suffer from relapse and their treatment options are limited with low survival. We are developing a therapeutic vaccine that induces anti-HPV T cells to specifically kill cancer cells. Our IP-protected target focuses on HPV16, the most prevalent and aggressive HPV type. The design enables Loma to raise stronger and broader immune responses in more individual patients, leading to a highly effective outcome.

BiotechnologyPharmaceuticals/Licensing

metaLead Therapeutics AG

Basel, Switzerland

Thu 9 Oct · 15:00 – 10:30

metaLead is a Swiss-based biotechnology company pioneering the development of first-in-class, metal-selective peptide therapeutics for the treatment of metal-related diseases and metal delivery systems. Our proprietary drug discovery platform integrates expertise in metal-binding chemistry, peptide engineering, and translational pharmacology to design compounds with unmatched potency and safety. Our lead program targets Wilson disease, a rare genetic disorder caused by copper accumulation in the liver and brain. Existing treatments are decades old, non-selective, and often poorly tolerated, leaving patients without effective options. metaLead’s lead candidate is a novel chelator designed to selectively bind and remove copper while preserving essential metals, offering the potential to halt disease progression and improve clinical outcomes. metaLead’s technology is rooted in years of academic research at the University of Zurich. It has been validated through extensive preclinical data packages in various metal-related conditions, including lead poisoning. The platform’s versatility enables rapid optimization of candidates for multiple metals and disease contexts, including other rare genetic disorders, toxic metal poisoning, and certain oncology indications where dysregulated metal homeostasis plays a role. Furthermore, metal excretion and specific metal delivery are within the reach of our platform. Our approach offers several competitive advantages: Benign nature, executing only the desired reactivity High selectivity to minimize off-target effects and preserve essential metals Peptide-based design enabling tunable pharmacokinetics and targeted tissue delivery Translational efficiency from bench to clinic via robust preclinical models metaLead is backed by leading life science accelerators, including the BioInnovation Institute (BII) and BaseLaunch, and has secured significant non-dilutive and convertible funding to advance its lead program through proof-of-concept studies. With a differentiated platform, strong intellectual property, and a focus on high unmet medical needs, metaLead is positioned to become the leader in metal-targeted therapeutics and to deliver transformative treatments to patients who currently have no adequate options.

BiotechnologyPharmaceuticals/Licensing

Mighto Therapeutics

Copenhagen, Denmark

Thu 9 Oct · 15:00 – 10:30

Mighto Therapeutics develops first-in-class small molecule-based genetic medicines for muscle and neurodegenerative diseases caused by mitochondrial dysfunction. Our treatments are designed a) to correct mitochondrial DNA defects that arise by inheritance or through aging and b) restore and enhance mitochondrial function. Our pipeline contains two programs: MGT-200, a clinic-ready small molecule for primary mitochondrial disorders (orphan drug) and MGT-100, a discovery stage small molecule for aging-related neurodegeneration. Mighto is a pre-seed stage biotech currently raising a seed financing.

BiotechnologyProfessional Services

ModernVivo, Inc.

Seattle, United States

Thu 9 Oct · 15:00 – 10:30

ModernVivo develops automated literature review software specifically designed for in vivo researchers. Our platform streamlines the process of searching for and reviewing in-vivo studies, reducing manual workloads that hinder study progress and drives up costs. With ModernVivo’s software, researchers and IACUC committees across pharmaceutical companies, contract research organizations, and academic labs can accelerate timelines, lower operational expenses, and improve translational success.

Biotechnology

SAPPIENS SAS

Tours, France

Thu 9 Oct · 15:00 – 10:30

SAPPIENS is a subsidiary of CXS Therapeutics, and has been established with the objective to develop CXS003, a 1st neuroprotective treatment in Parkinson's disease. CXS003 is a patented, innovative and de-risked program with the potential to become the 1st disease-modifying treatment in Parkinson disease. Preclinical results have shown promising results for CXS003 neuroprotective properties in Parkinson's disease and other neuroprotective applications (Alzheimer, ALS and Huntington diseases), all covered under the patents. CXS003 phase 2 clinical trial readiness expected in early 2026. SAPPIENS is currently raising seed financing.

Biotechnology

Serenatis Bio

Cambridge, United Kingdom

Thu 9 Oct · 15:00 – 10:30

Serenatis Bio is a start-up biotech developing three novel drugs to treat obsessive-compulsive disorder (OCD), a common yet poorly treated and devastating mental illness with huge unmet need and commercial opportunity. Each drug has a different mechanism of action - targeting glutamate and dopamine receptors - using precision medicine to identify which OCD patients will respond to which drug.

BiotechnologyConsulting ServicesCRODrug DeliveryInvestment BankInvestor - AngelInvestor - Family OfficeInvestor - VCInvestor - OtherPharmaceuticals/LicensingProfessional ServicesTech TransferPharmaceuticals

SWISS IMMUNE | Amedioo EDC

Meggen, Switzerland

Thu 9 Oct · 15:00 – 10:30

SWISS IMMUNE | Amedioo EDC is a breakthrough IO Immuno - Oncology Company in Switzerland leveraging established technologies and science developed over 2 decades with a vector based approach to treat multiple cancer types. We also leverage the results and efficacy data from animal health (ANNIMO Health EDC AG; annimoo.com; presented in March 2025 with full financing committed in May 2025. We aim to replicate same success in human health 2025 to 2028+ in various cancer types, too. The technology works beautifully. Data from Phase I and pre-clinical studies in humans and animals (horses demonstrate safety broadly and "similar efficacy" to animal health exceeding today's standards of care worldwide. Results and data are encouraging in multiple forms of skin cancer (melanoma), for pelvic, thoraic and rare to pediatric cancers. Outside of head-and-neck cancer, the core indication of founding company (out of scope for SWISS IMMUNE, we are developing other indications), we intend to develop the technology in 3 core areas with targeted, focused investments: (A) Pelvic Cancers (B) Melanoma & Skin Cancers (C )Thoracic Cancers (D) Rare Cancers "Right Capital": We aim to find the rightinvestors to take each area forward (A-D) until end of positive Phase II. We have defined GMP production and focus on speed and low costs (university settings with AI, own CRO) and have defined development plans. We target investors, to exit in 3-4 years after Phase II with a pre-IPO / IPO or will partner and / or exit by single product sales. We aim at returning 4.5 the face value of entrusted capital at year 4-5 (as a minimum) given success.

Biotechnology

SynuCa Therapeutics

København N, Denmark

Thu 9 Oct · 15:00 – 10:30

At Synuca Tx we are dedicated to developing a much needed first-in-class disease-modifying therapy for patients suffering from Parkinson’s Disease (PD) and the associated brain disorders orphan disease Multiple System Atrophy (MSA) and Dementia with Lewy Bodies, combined affecting >10 million individuals globally. Synuca Tx, spurred by ground-breaking research from Aarhus University, pioneers a novel treatment strategy to prevent α-Synuclein aggregate-induced Ca2+ dysregulation and the subsequent cascade of events leading to neurodegeneration and symptoms. Our revolutionizing approach, involves an orally available small molecule, SYN4569, targeting of the Ca2+ transporter, SERCA. Based on our differentiated MoA, SYN4569 presents as a promising and safe clinically relevant compound capable of preventing both de novo α-Synuclein aggregation and the pathological prion-like α-Synuclein spread, while improving motor performance and neuroprotection in three highly accredited PD and MSA pre-clinical mouse models. Altogether, SynuCa Tx are in a unique position to resolve the gigantic unmet clinical need in these otherwise incurable brain disorders, by salvaging the underlying root disease mechanism.